GlassScriptPhysician profile
Phyu Phyu Win
NPI 1801535695
$1,398.44
in general payments reported to CMS, 2019-2025
20 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $129 · 2024: $659 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $217.53 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $206.90 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.54 | 2023-2025 | Jardiance |
| Abiomed | $157.66 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $149.96 | 2024 | Farxiga, Wainua |
| Amgen INC. | $81.07 | 2024-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $59.56 | 2024 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $55.18 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $31.96 | 2024 | |
| Csl Behring | $31.37 | 2023 | Kcentra |
| Kiniksa Pharmaceuticals, LTD. | $31.17 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $31.05 | 2025 | |
| Scpharmaceuticals INC. | $30.29 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.14 | 2025 | Onpattro |
| Intercept Pharmaceuticals, INC. | $20.55 | 2023 | Ocaliva |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $16.79 | 2025 | Attruby |
| Novo Nordisk INC | $14.87 | 2025 | Wegovy |
| Exact Sciences Corporation | $14.50 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $14.21 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $14.14 | 2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyu Phyu Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.